BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23739000)

  • 1. mTOR inhibitors as a new therapeutic option for epilepsy.
    Curatolo P; Moavero R
    Expert Rev Neurother; 2013 Jun; 13(6):627-38. PubMed ID: 23739000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis.
    Citraro R; Leo A; Constanti A; Russo E; De Sarro G
    Pharmacol Res; 2016 May; 107():333-343. PubMed ID: 27049136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR dysregulation and tuberous sclerosis-related epilepsy.
    Curatolo P; Moavero R; van Scheppingen J; Aronica E
    Expert Rev Neurother; 2018 Mar; 18(3):185-201. PubMed ID: 29338461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of mTOR inhibitors in epilepsy treatment.
    Sadowski K; Kotulska-Jóźwiak K; Jóźwiak S
    Pharmacol Rep; 2015 Jun; 67(3):636-46. PubMed ID: 25933981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the mTOR signaling pathway in epilepsy.
    Meng XF; Yu JT; Song JH; Chi S; Tan L
    J Neurol Sci; 2013 Sep; 332(1-2):4-15. PubMed ID: 23773767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
    Wong M
    Epilepsia; 2010 Jan; 51(1):27-36. PubMed ID: 19817806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy.
    Russo E; Citraro R; Donato G; Camastra C; Iuliano R; Cuzzocrea S; Constanti A; De Sarro G
    Neuropharmacology; 2013 Jun; 69():25-36. PubMed ID: 23092918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target.
    Galanopoulou AS; Gorter JA; Cepeda C
    Epilepsia; 2012 Jul; 53(7):1119-30. PubMed ID: 22578218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials.
    Wong M
    Expert Rev Neurother; 2013 Jun; 13(6):657-69. PubMed ID: 23739003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibition in epilepsy: rationale and clinical perspectives.
    Ostendorf AP; Wong M
    CNS Drugs; 2015 Feb; 29(2):91-9. PubMed ID: 25633849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
    Rensing N; Han L; Wong M
    Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infantile tauopathies: Hemimegalencephaly; tuberous sclerosis complex; focal cortical dysplasia 2; ganglioglioma.
    Sarnat HB; Flores-Sarnat L
    Brain Dev; 2015 Jun; 37(6):553-62. PubMed ID: 25451314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology.
    Jeong A; Wong M
    Curr Neurol Neurosci Rep; 2016 Dec; 16(12):102. PubMed ID: 27815691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DEPDC5 as a potential therapeutic target for epilepsy.
    Myers KA; Scheffer IE
    Expert Opin Ther Targets; 2017 Jun; 21(6):591-600. PubMed ID: 28406046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development.
    Jeong A; Wong M
    J Child Neurol; 2018 Jan; 33(1):55-63. PubMed ID: 29246093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy.
    Ryther RC; Wong M
    Curr Neurol Neurosci Rep; 2012 Aug; 12(4):410-8. PubMed ID: 22544534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
    Schubert-Bast S; Rosenow F; Klein KM; Reif PS; Kieslich M; Strzelczyk A
    Epilepsy Behav; 2019 Feb; 91():94-98. PubMed ID: 29941212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR signaling in epilepsy: insights from malformations of cortical development.
    Crino PB
    Cold Spring Harb Perspect Med; 2015 Apr; 5(4):. PubMed ID: 25833943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.